{"id":"W4411028189","doi":"10.1200/jco.2025.43.17_suppl.lba4","title":"Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent <i>ESR1</i> mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Endocrine system; Disease; Oncology; First line treatment; Palbociclib; Internal medicine; Cancer; Hormone; Chemotherapy; Metastatic breast cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005942985,0.0003066365,0.001623337,0.0002354002,0.00009371643,0.000008536925,0.00014645,0.0001313457,0.00004015413],"category_scores_gemma":[0.00022971,0.0001701576,0.0004078301,0.0003256038,0.0003854398,0.0001727216,0.00002024141,0.0003309872,1.243731e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003519985,"about_ca_system_score_gemma":0.002354269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000751981,"about_ca_topic_score_gemma":0.0003720355,"domain_scores_codex":[0.9961034,0.0002290181,0.002606931,0.0003348822,0.0004173199,0.0003084607],"domain_scores_gemma":[0.994904,0.001497932,0.002119229,0.0003050925,0.0008910399,0.0002826672],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7181026,0.01658782,0.0372973,0.0002033599,0.0006969576,0.00004454927,0.0001859938,0.002570601,0.000485382,0.00001293714,0.00001577901,0.2237967],"study_design_scores_gemma":[0.8401499,0.04114987,0.1065539,0.001848168,0.0008895208,0.00001797335,0.0001461344,0.000324663,0.00445207,0.00008467402,0.004201527,0.0001815384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814671,0.003271618,0.0004549769,0.01054889,0.0006753927,0.003426718,0.0001340976,0.00001026339,0.00001096315],"genre_scores_gemma":[0.9921106,0.005206312,0.001517151,0.0003044229,0.0003421404,0.0004133122,0.00002367682,0.00003421016,0.00004821976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2236151,"threshold_uncertainty_score":0.6938825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09887842059387833,"score_gpt":0.4985457819358709,"score_spread":0.3996673613419925,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}